BridgeBio to Present Additional Phase 3 ATTRibute-CM Study Analyses at 2024 ISA

BridgeBio Pharma, Inc., a biopharmaceutical company concentrating on genetic diseases and cancers, will be prominently featured at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, from May 26 to 30, 2024. During this event, BridgeBio will present 12 oral and moderated poster presentations detailing their latest research and findings.

In connection with the symposium, BridgeBio will conduct an investor call on May 29, 2024, at 5:30 pm ET. This call will cover the latest analyses and positive data from the ATTRibute-CM Phase 3 trial, as well as emerging real-world evidence on ATTR-CM. The call will feature presentations by notable experts, including Dr. Mathew Maurer from Columbia University Irving Medical Center and Dr. Ahmad Masri from Oregon Health & Science University.

BridgeBio was established in 2015 and operates as a commercial-stage biopharmaceutical company. The company is dedicated to the discovery, development, and delivery of innovative medicines that address genetic diseases and cancers with clear genetic causes. Their development pipeline spans from preliminary scientific research to advanced clinical trials. The team at BridgeBio consists of experienced professionals committed to leveraging advancements in genetic medicine to benefit patients promptly.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!